F-star Therapeutics(SBPH)

chuminhua2019-10-19 15:24

10/17， Spring Bank Pharmaceuticals$Spring Bank制药(SBPH)$ 发布与Gilead合作的正在进行中的II期研究12周的中期数据。研究评估该公司的inarigivir和Gilead的Vemlidy® (替诺福韦艾拉酚胺 TAF 25mg) 联用治疗HBV感染的有效性和安全性。30例患者接受低剂量inarigivir 50mg+Vemlidy，12例患者接受V...查看全文

usbiostock2018-08-03 09:53

$Spring Bank Pharmaceuticals, Inc.(SBPH)$ 公司公布ACHIEVE临床2期试验Part A第三组（inarigivir 100mg）阳性数据，第四组（inarigivir 200mg）数据预计在2018年第4季度公布。查看全文

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001132  Size: 16 KB 网页链接

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001133  Size: 11 KB 网页链接

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001134  Size: 11 KB 网页链接

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001135  Size: 11 KB 网页链接

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001129  Size: 17 KB 网页链接

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001130  Size: 16 KB 网页链接

$F-star Therapeutics(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905718-20-001131  Size: 19 KB 网页链接

$Spring Bank制药(SBPH)$ 8-K Current report, items 2.01, 3.03, 4.01, 5.01, 5.02, 5.03, 5.07, 7.01, and 9.01 Accession Number: 0001193125-20-299470  Act: 34  Size: 9 MB 网页链接

$Spring Bank制药(SBPH)$ 425 Prospectuses and communications, business combinations Accession Number: 0001564590-20-052221  Act: 34  Size: 79 KB 网页链接

$Spring Bank制药(SBPH)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001564590-20-052214  Act: 34  Size: 225 KB 网页链接